TY - JOUR
AR - JDMC-2022-1-102
TI - Effect of Gplife Advance Diabetic Support on Time in Range in Type 2 Diabetes Mellitus Patients: A Case Report
AU - Shridhar, Pandya
AU - Chetan, Savaliya
JO - Journal of Diabetes Metabolism and its Complications
PY - 2022
DA - Fri 13, Jan 2023
SN - 2674-4163
DO - http://dx.doi.org/10.31487/j.JDMC.2022.01.02
UR - https://www.sciencerepository.org/effect-of-gplife-advance-diabetic_JDMC-2022-1-102 
KW - Time in range (TIR), adjuvant therapy, type 2 diabetes mellitus, anti-diabetic
AB - This case report documents 20 patients suffering from uncontrolled type 2 diabetes mellitus, presenting complaints of fluctuating blood glucose levels. The parameters like fasting and postprandial blood glucose, HbA1c and C- peptide levels of patients were evaluated. These patients were then advised an adjuvant therapy of Gplife advanced diabetic support tablets along with their daily insulin injections. After 60 days of treatment, the therapy was discontinued, and patients were subjected to continuous glucose monitoring for 8 days and time in range (TIR) percentage was calculated. Also, the fasting and postprandial blood glucose, HbA1c and C-peptide levels were estimated. The average TIR percentage was found to be 93.2%, whereas the time above range (TAR) and time below range (TBR) was 6.8 % and 0 % respectively, which indicates that the patients had a negligible incidence of hyper and hypoglycemia after 60 days of treatment. There was a significant decrease by 61 % in HbA1c levels, 40.05 % in fasting blood glucose levels and 34.29 % in postprandial blood glucose levels (p<0.001). C-peptide levels increased by 1.38 folds after 60 days of treatment. Also, there were no evidence of diabetic comorbidities. Thus, indicating a marked improvement in the diabetic condition and overall quality of life in patients.